The effects of 17β-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis

Iris L. Romero, Wooseok Lee, Anirban Mitra, Ilyssa O. Gordon, Yan Zhao, Payton Leonhardt, Carla V. Penicka, Keeley L. Mui, Thomas N. Krausz, Geoffrey L. Greene, Ernst Lengyel

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objective: To test if estrogen promotes carcinogenesis in vitro and in a genetic mouse model of ovarian cancer and whether its effects can be inhibited by a novel selective estrogen receptor modulator (SERM), bazedoxifene. Methods: Bazedoxifene was synthesized and it was confirmed that the drug abrogated the uterine stimulatory effect of 17β-estradiol in mice. To determine if hormones alter tumorigenesis in vivo LSL-K-ras G12D/+Pten loxP/loxP mice were treated with vehicle control, 17β-estradiol or bazedoxifene. Hormone receptor status of a cell line established from LSL-K-ras G12D/+Pten loxP/loxP mouse ovarian tumors was characterized using Western blotting and immunohistochemistry. The cell line was treated with hormones and invasion assays were performed using Boyden chambers and proliferation was assessed using MTT assays. Results: In vitro 17β-estradiol increased both the invasion and proliferation of ovarian cancer cells and bazedoxifene reversed these effects. However, in the genetic mouse model neither treatment with 17β-estradiol nor bazedoxifene changed mean tumor burden when compared to treatment with placebo. The mice in all treatment groups had similar tumor incidence, metastatic nodules and ascites. Conclusion: While 17β-estradiol increases the invasion and proliferation of ovarian cancer cells, these effects do not translate into increased tumor burden in a genetic mouse model of endometrioid ovarian cancer. Likewise, while the SERM reversed the detrimental effects of estrogen in vitro, there was no change in tumor burden in mice treated with bazedoxifene. These findings demonstrate the complex interplay between hormones and ovarian carcinogenesis.

Original languageEnglish (US)
Pages (from-to)134-141
Number of pages8
JournalGynecologic Oncology
Volume124
Issue number1
DOIs
StatePublished - Jan 2012
Externally publishedYes

Fingerprint

Selective Estrogen Receptor Modulators
Estradiol
Carcinogenesis
Ovarian Neoplasms
Genetic Models
Tumor Burden
Hormones
Estrogens
Cell Line
bazedoxifene
Ascites
Neoplasms
Therapeutics
Western Blotting
Immunohistochemistry
Placebos
Incidence

Keywords

  • 17β-estradiol
  • Genetic mouse model
  • Hormone replacement therapy
  • Ovarian cancer
  • Selective estrogen receptor modulators

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

The effects of 17β-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis. / Romero, Iris L.; Lee, Wooseok; Mitra, Anirban; Gordon, Ilyssa O.; Zhao, Yan; Leonhardt, Payton; Penicka, Carla V.; Mui, Keeley L.; Krausz, Thomas N.; Greene, Geoffrey L.; Lengyel, Ernst.

In: Gynecologic Oncology, Vol. 124, No. 1, 01.2012, p. 134-141.

Research output: Contribution to journalArticle

Romero, IL, Lee, W, Mitra, A, Gordon, IO, Zhao, Y, Leonhardt, P, Penicka, CV, Mui, KL, Krausz, TN, Greene, GL & Lengyel, E 2012, 'The effects of 17β-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis', Gynecologic Oncology, vol. 124, no. 1, pp. 134-141. https://doi.org/10.1016/j.ygyno.2011.08.026
Romero, Iris L. ; Lee, Wooseok ; Mitra, Anirban ; Gordon, Ilyssa O. ; Zhao, Yan ; Leonhardt, Payton ; Penicka, Carla V. ; Mui, Keeley L. ; Krausz, Thomas N. ; Greene, Geoffrey L. ; Lengyel, Ernst. / The effects of 17β-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis. In: Gynecologic Oncology. 2012 ; Vol. 124, No. 1. pp. 134-141.
@article{bf4d3ac7bdc540e0b42a745cf09a1448,
title = "The effects of 17β-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis",
abstract = "Objective: To test if estrogen promotes carcinogenesis in vitro and in a genetic mouse model of ovarian cancer and whether its effects can be inhibited by a novel selective estrogen receptor modulator (SERM), bazedoxifene. Methods: Bazedoxifene was synthesized and it was confirmed that the drug abrogated the uterine stimulatory effect of 17β-estradiol in mice. To determine if hormones alter tumorigenesis in vivo LSL-K-ras G12D/+Pten loxP/loxP mice were treated with vehicle control, 17β-estradiol or bazedoxifene. Hormone receptor status of a cell line established from LSL-K-ras G12D/+Pten loxP/loxP mouse ovarian tumors was characterized using Western blotting and immunohistochemistry. The cell line was treated with hormones and invasion assays were performed using Boyden chambers and proliferation was assessed using MTT assays. Results: In vitro 17β-estradiol increased both the invasion and proliferation of ovarian cancer cells and bazedoxifene reversed these effects. However, in the genetic mouse model neither treatment with 17β-estradiol nor bazedoxifene changed mean tumor burden when compared to treatment with placebo. The mice in all treatment groups had similar tumor incidence, metastatic nodules and ascites. Conclusion: While 17β-estradiol increases the invasion and proliferation of ovarian cancer cells, these effects do not translate into increased tumor burden in a genetic mouse model of endometrioid ovarian cancer. Likewise, while the SERM reversed the detrimental effects of estrogen in vitro, there was no change in tumor burden in mice treated with bazedoxifene. These findings demonstrate the complex interplay between hormones and ovarian carcinogenesis.",
keywords = "17β-estradiol, Genetic mouse model, Hormone replacement therapy, Ovarian cancer, Selective estrogen receptor modulators",
author = "Romero, {Iris L.} and Wooseok Lee and Anirban Mitra and Gordon, {Ilyssa O.} and Yan Zhao and Payton Leonhardt and Penicka, {Carla V.} and Mui, {Keeley L.} and Krausz, {Thomas N.} and Greene, {Geoffrey L.} and Ernst Lengyel",
year = "2012",
month = "1",
doi = "10.1016/j.ygyno.2011.08.026",
language = "English (US)",
volume = "124",
pages = "134--141",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - The effects of 17β-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis

AU - Romero, Iris L.

AU - Lee, Wooseok

AU - Mitra, Anirban

AU - Gordon, Ilyssa O.

AU - Zhao, Yan

AU - Leonhardt, Payton

AU - Penicka, Carla V.

AU - Mui, Keeley L.

AU - Krausz, Thomas N.

AU - Greene, Geoffrey L.

AU - Lengyel, Ernst

PY - 2012/1

Y1 - 2012/1

N2 - Objective: To test if estrogen promotes carcinogenesis in vitro and in a genetic mouse model of ovarian cancer and whether its effects can be inhibited by a novel selective estrogen receptor modulator (SERM), bazedoxifene. Methods: Bazedoxifene was synthesized and it was confirmed that the drug abrogated the uterine stimulatory effect of 17β-estradiol in mice. To determine if hormones alter tumorigenesis in vivo LSL-K-ras G12D/+Pten loxP/loxP mice were treated with vehicle control, 17β-estradiol or bazedoxifene. Hormone receptor status of a cell line established from LSL-K-ras G12D/+Pten loxP/loxP mouse ovarian tumors was characterized using Western blotting and immunohistochemistry. The cell line was treated with hormones and invasion assays were performed using Boyden chambers and proliferation was assessed using MTT assays. Results: In vitro 17β-estradiol increased both the invasion and proliferation of ovarian cancer cells and bazedoxifene reversed these effects. However, in the genetic mouse model neither treatment with 17β-estradiol nor bazedoxifene changed mean tumor burden when compared to treatment with placebo. The mice in all treatment groups had similar tumor incidence, metastatic nodules and ascites. Conclusion: While 17β-estradiol increases the invasion and proliferation of ovarian cancer cells, these effects do not translate into increased tumor burden in a genetic mouse model of endometrioid ovarian cancer. Likewise, while the SERM reversed the detrimental effects of estrogen in vitro, there was no change in tumor burden in mice treated with bazedoxifene. These findings demonstrate the complex interplay between hormones and ovarian carcinogenesis.

AB - Objective: To test if estrogen promotes carcinogenesis in vitro and in a genetic mouse model of ovarian cancer and whether its effects can be inhibited by a novel selective estrogen receptor modulator (SERM), bazedoxifene. Methods: Bazedoxifene was synthesized and it was confirmed that the drug abrogated the uterine stimulatory effect of 17β-estradiol in mice. To determine if hormones alter tumorigenesis in vivo LSL-K-ras G12D/+Pten loxP/loxP mice were treated with vehicle control, 17β-estradiol or bazedoxifene. Hormone receptor status of a cell line established from LSL-K-ras G12D/+Pten loxP/loxP mouse ovarian tumors was characterized using Western blotting and immunohistochemistry. The cell line was treated with hormones and invasion assays were performed using Boyden chambers and proliferation was assessed using MTT assays. Results: In vitro 17β-estradiol increased both the invasion and proliferation of ovarian cancer cells and bazedoxifene reversed these effects. However, in the genetic mouse model neither treatment with 17β-estradiol nor bazedoxifene changed mean tumor burden when compared to treatment with placebo. The mice in all treatment groups had similar tumor incidence, metastatic nodules and ascites. Conclusion: While 17β-estradiol increases the invasion and proliferation of ovarian cancer cells, these effects do not translate into increased tumor burden in a genetic mouse model of endometrioid ovarian cancer. Likewise, while the SERM reversed the detrimental effects of estrogen in vitro, there was no change in tumor burden in mice treated with bazedoxifene. These findings demonstrate the complex interplay between hormones and ovarian carcinogenesis.

KW - 17β-estradiol

KW - Genetic mouse model

KW - Hormone replacement therapy

KW - Ovarian cancer

KW - Selective estrogen receptor modulators

UR - http://www.scopus.com/inward/record.url?scp=83055181123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83055181123&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2011.08.026

DO - 10.1016/j.ygyno.2011.08.026

M3 - Article

C2 - 21996264

AN - SCOPUS:83055181123

VL - 124

SP - 134

EP - 141

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -